Myriad Genetics and Onsite Women’s Health Partner to Help More Women Understand Breast Cancer Risk
22 Agosto 2023 - 10:00AM
Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing
and precision medicine, and Onsite Women’s Health, a leading
national provider of breast health services, today announced the
launch of a new breast cancer risk assessment program to help more
women understand their breast cancer risk.
The collaboration combines the strengths of Myriad’s hereditary
breast cancer/risk assessment resources, MyRisk® with
RiskScore®, and Onsite’s deep expertise in breast health services,
including mammography and breast ultrasound. The program is
expected to deliver personalized insights to better inform clinical
care for the more than 400,000 patients Onsite serves
nationwide.
The new collaboration will help identify and screen younger
patients who are at an increased risk for breast cancer. The
American College of Radiology and the Society of Breast Imaging
recommend that all women be evaluated for breast cancer risk no
later than age 30 to help identify those at higher risk who would
benefit from early screening. Current guidelines also
state that women at high risk of breast cancer (calculated >20%
lifetime) and/or genetically-based increased risk should begin
annual screening breast MRI at age 25–30, and annual screening
mammography at age 30.
“Today, there are nearly one in four unaffected women who meet
hereditary cancer testing criteria1. Our collaboration with Onsite
makes it easy to access genetic testing and breast cancer risk
assessment at the point of care for the roughly 25% of women who
are eligible for testing,” said Paul Diaz, president and CEO,
Myriad Genetics. “This program can help identify more high-risk
patients and guide personalized medical management plans for breast
cancer risk reduction and early detection strategies.”
“In partnership with forward-thinking providers across the
country, Onsite Women’s Health offers comprehensive mammography
services with clinical expertise, innovative technology and
proprietary protocols that delivers personalized, convenient breast
care for the patient,” said Brian Marger, CEO at Onsite Women’s
Health. “As a forerunner in genetic testing and precision medicine,
Myriad has proven to be a strong partner as we enhance our
capabilities to more deeply understand each woman’s individualized
breast cancer risk and detect cancer earlier while it is the most
treatable.”
The program will be offered to one third of Onsite’s OBGYN and
primary care physician partnerships in the coming months, with
further expansion expected in 2024.
About Myriad GeneticsMyriad Genetics is a
leading genetic testing and precision medicine company dedicated to
advancing health and well-being for all. Myriad develops and offers
genetic tests that help assess the risk of developing disease or
disease progression and guide treatment decisions across medical
specialties where genetic insights can significantly improve
patient care and lower healthcare costs. For more information,
visit www.myriad.com.
About Onsite Women’s Health In partnership with
forward-thinking providers across the country, Onsite Women’s
Health offers comprehensive breast imaging services – including 3D
screening mammography, automated screening breast ultrasound,
diagnostic mammography/breast ultrasound and lifetime breast cancer
risk assessment. Onsite is committed to saving more women’s lives
through earlier cancer detection and is materially impacting breast
cancer screening compliance and detection rates through offering
convenient access to mammography, contracting with breast-focused
radiologists and utilizing the most innovative equipment and
AI-powered technology available on the market. By offering the
ability to risk assess patients using tools powered by AI, Onsite
supports the providers’ ability to offer personalized and precise
care plans to patients based on individual risk profiles. Onsite
services increase patient satisfaction, improve breast health
services and offer an additional revenue opportunity for practice
partners. Since its founding in 2008, Onsite has performed more
than two million exams across 26 states.
1 DeFrancesco, et al. Obstetrics & Gynecology, Nov
2018
Safe Harbor Statement This press
release contains “forward-looking statements” within the meaning of
the Private Securities Litigation Reform Act of 1995, including
statements relating to the benefits of the new breast cancer risk
assessment program, including that it will increase access to
genetic testing and help identify and screen younger patients who
are at an increased risk for breast cancer, and that the program
will be offered to one third of Onsite’s OBGYN and PCP partnerships
in the coming months, with further expansion expected in 2024.
These “forward-looking statements” are management’s expectations of
future events as of the date hereof and are subject to known and
unknown risks and uncertainties that could cause actual results,
conditions, and events to differ materially and adversely from
those anticipated. Such factors include those risks described in
the company’s filings with the U.S. Securities and Exchange
Commission, including the company’s Annual Report on Form 10-K
filed on March 1, 2023, as well as any updates to those risk
factors filed from time to time in the company’s Quarterly Reports
on Form 10-Q or Current Reports on Form 8-K. Myriad is not under
any obligation, and it expressly disclaims any obligation, to
update or alter any forward-looking statements, whether as a result
of new information, future events or otherwise except as required
by law.
Media
Contact: |
|
Investor
Contact: |
Glenn Farrell |
|
Matt Scalo |
(385) 318-3718 |
|
(801) 584-3532 |
PR@myriad.com |
|
IR@myriad.com |
Myriad Genetics (NASDAQ:MYGN)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Myriad Genetics (NASDAQ:MYGN)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024